Ovid Therapeutics (OVID)
NASDAQ:OVID
Want to see OVID full AI Analyst Report?
OVID Stock Chart & Stats
$2.91
-$0.03(-2.93%)
At close: 4:00 PM EST
$2.91
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.29 - $3.11
Previous CloseN/A
Volume22.63K
Average Volume (3M)2.29M
Market Cap
$423.67M
Enterprise Value$226.56M
Total Cash (Recent Filing)$155.52M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding186,640,100
10 Day Avg. Volume3,433,532
30 Day Avg. Volume2,285,979
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue31.81
Enterprise Value/Gross Profit31.97
Enterprise Value/Ebitda-9.44
Forecast
1Y Price Target
$5.33Price Target Upside83.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$221.88K
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetA materially lower debt-to-equity ratio signals limited financial leverage, reducing default and covenant risks. This structural strength preserves strategic optionality, lets management prioritize R&D investment over debt servicing, and improves resilience to clinical delays or financing volatility.
Recent Capital Raises & RunwayMaterial financings and warrant exercises meaningfully extended the company's cash runway into late 2028, lowering short-term refinancing risk. This durable funding allows planned Phase 1/early patient studies to proceed, reducing probability of disruptive emergency financings and preserving program optionality.
Pipeline Progress & Clinical MomentumAdvancing OV329 with favorable Phase 1 safety and expanding indications, plus regulatory clearance for OV4071 Phase 1, increases execution credibility and de-risks near-term value inflection points. Progress across two programs diversifies clinical news flow and supports potential future partnering or milestone revenues.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow reflects ongoing burn from R&D and operations. Over 2–6 months this structural cash deficit necessitates ongoing access to capital or milestone payments; delays or trial setbacks would quickly increase dilution risk and constrain strategic alternatives.
Sustained Losses & Volatile RevenueThe company lacks stable product revenue and has shown sharply volatile top-line results with persistent negative margins. This structural revenue instability hampers the ability to build predictable profitability, complicates long-term planning, and increases reliance on episodic financing or partnerships for operations.
Clinical & Execution Concentration RiskAs a small, clinical-stage biotech with no marketed products and a 23-person team, Ovid faces concentrated execution risk. Regulatory setbacks, trial enrollment issues, or key-person dependencies could materially delay programs and value creation, increasing the need for external partnerships or financing.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics’s price range in the past 12 months?
Ovid Therapeutics lowest stock price was $0.28 and its highest was $3.10 in the past 12 months.
What is Ovid Therapeutics’s market cap?
Ovid Therapeutics’s market cap is $423.67M.
When is Ovid Therapeutics’s upcoming earnings report date?
Ovid Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 59 days.
How were Ovid Therapeutics’s earnings last quarter?
Ovid Therapeutics released its earnings results on May 12, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.004.
Is Ovid Therapeutics overvalued?
According to Wall Street analysts Ovid Therapeutics’s price is currently Undervalued.
Does Ovid Therapeutics pay dividends?
Ovid Therapeutics does not currently pay dividends.
What is Ovid Therapeutics’s EPS estimate?
Ovid Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics have?
Ovid Therapeutics has 186,640,100 shares outstanding.
What happened to Ovid Therapeutics’s price movement after its last earnings report?
Ovid Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went up 2.867%.
Which hedge fund is a major shareholder of Ovid Therapeutics?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.33 (83.28% Upside)
$5.33 (83.28% Upside)
Blogger Sentiment
Bullish
OVID Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
669.49%
12-Months-Change
Fundamentals
Return on Equity
-22.51%
Trailing 12-Months
Asset Growth
176.32%
Trailing 12-Months
Company Description
Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
OVID Company Deck
OVID Earnings Call
Q4 2026
0:00 / 0:00
OVID Stock 12 Month Forecast
Average Price Target
$5.33
▲(83.28% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
6.98% Insiders
7.06% Mutual Funds
33.10% Other Institutional Investors
49.80% Public Companies and
Individual Investors